je.st
news
Tag: pharmaceuticals
Otsuka Pharmaceutical To Acquire Avanir Pharmaceuticals
2014-12-03 06:54:28| drugdiscoveryonline News Articles
Otsuka Pharmaceutical Co., Ltd. is pleased to announce an agreement with Avanir Pharmaceuticals, Inc. (“Avanir”) in which Otsuka America, Inc., a US subsidiary, acquires Avanir for USD 3.5 billion in an all-cash tender offer
Tags: acquire
pharmaceutical
pharmaceuticals
otsuka
20 Job Openings in Cheshire: Alexion Pharmaceuticals, Cheshire Academy, United Technologies and More
2014-11-30 02:31:21| Biotech - Topix.net
Sr Manager / Associate Director, Global aHUS Marketing Reports to: Director, Global aHUS Medical Marketing Location: Cheshire, CT Alexion Pharmaceuticals, Inc. is a... One of our clients a publicly listed with 2 Billion Dollars in revenue BioPharmaceutical company is looking for an Associate Director of Finance to join their team, this role will... IT Validation Manager will be responsible for registration and validation of IT systems.
Tags: more
united
job
technologies
Criminal Global Cartel Focus on Generic Pharmaceuticals
2014-11-26 19:49:03| Auto Parts - Topix.net
The Antitrust Division is nearing the end of its largest, record-setting criminal cartel investigation global auto parts suppliers. It has been a sprawling investigation that has leaped from product-to-product in the auto parts industry.
Tags: global
focus
criminal
generic
Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA
2014-11-25 16:58:52| Biotech - Topix.net
Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy . SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.
Tags: with
study
children
phase
Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
2014-11-24 14:00:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Language: English Contact: MerckMedia:Pam Eisele267-305-3558orKim Hamilton908-740-1863 / 908-391-0131orInvestors:Justin Holko908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
type
application
medical
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] next »